The Investment Opportunity

- Series A raise of US$20M (for a 33% equity holding) to fund commercialization of a first-in-class antibody, Miltuximab®, targeting cancers with a major unserved medical need in a high value market.
- Miltuximab® **is a first-in-class treatment for certain solid tumours** (including those listed below) that can share in the US$51B (and growing) immuno-oncology cancer treatment market.

Cancer	2018 New Cases Diagnosed	% All Cancers*	% Mortality Rate Per Annum	GPC-1 Key Reference
Prostate	1,276,106	7.1	28.1	Russell et al Cancer Immunol. Immunother. (2004) 53: 995-1004
Breast	2,088,849	11.6	30.0	Matsuda et al Cancer Res 2001;61:5562-69
Bladder	549,393	3.0	36.4	Walker et al, J Urol. (1989) 142: 1578-83
Pancreas	458,918	2.5	94.2	Lu et al, Cancer Medicine (2017) 6:1181
Brain, nervous system	296,851	1.6	81.2	Saito et al J. WNeurosurg.(2017) 105: 282-8
Esophagus	572,034	3.2	88.9	Harada et al Oncotarget (2017) 8:24741
Mesothelioma	30,443	0.2	84.0	Amatya et al Mod Pathol. 2018 31(5):809-15
Total	5,242,151			

- Results from our first-in-human clinical trial demonstrated great potential in targeting cancer combined with an excellent safety profile (i.e. no drug related adverse events were observed in any patient) establishing a strong commercial foundation for our approach.
- Commercialization of this exciting technology is enhanced by a strong propriety position around the target, Glypican-1 – which is present in a number of different solid tumour types.

Pathway to Shareholder Returns

- GlyTherix intends to commercialise the drug either by licensing or a trade sale to a large pharmaceutical or biotech company capable of taking the drug through regulatory approvals and into the global market.
- Alternatively, a stock exchange listing (US or Europe) will be considered when sufficient data/value has been created.
- GlyTherix continues to engage with Key Opinion Leaders (KOLs) and potential licensees ensuring Miltuximab® development is aligned with clinical, commercial and patient expectations.

Recent Example Deals in the Immuno-oncology space

Licensor	Licensee	Product	Stage	Upfront US$M	Total Deal US$M
2017					
Viralytics	Merck	Immunotherapy	Phase 1/2		395
Immatics GmbH	Amgen	Bispecific antibodies	Discovery	30	1,000
2018					
Adv Accelerator Applications	Novartis	Radio Immunotherapy	Marketed, Phase 2/3		3,900
Endocyte	Novartis	Radio Immunotherapy	Phase 2/3		2,100
2019					
Adaptive Biotechnologies	Genentech	T-cell cancer therapies	Preclinical	$300	2.3 Bn
Tenebio	Abbvie	BCMA-CD3 bispecific	Preclinical	$90	90+
Immune Design	Merck	IO tech & Ph1/2 drugs	Ph1/2	300	300

Use of Funds

- Conduct a Phase 1 theranostic trial with ^{89}Zr and ^{177}Lu radiolabeled Miltuximab® to generate safety and efficacy data that we expect to demonstrate a compelling value proposition for licensees
- Manufacture GMP humanized version of antibody for use in future clinical trials in US and other countries
- Perform further pre-clinical experiments or other cancer indications

- Company is eligible for 43.5% cash rebate from government for eligible R&D spend - this extends funding runway.

^{67}Gallium Miltuximab ® First-In-Human Safety Study

- The company has completed its First-in-Human trial having dosed 12 prostate, bladder and pancreatic cancer patients.
- No drug related adverse events have been observed in these patients.
- Prostate, bladder and pancreatic cancers will be studied in the Phase 1 trial



^{177}Lu and 89Zr-Miltuximab® mouse xenograft model



All mice had human prostate cancer tumors
Mice treated with 10MBq Lu^{177}-Miltuximab showed good inhibition of tumor growth (A) and good survival (B)



Dynamic microPET/CT imaging showing tumour accumulation of ^{89}Zr-Miltuximab® 7 days post-infusion

Miltuximab®-anti-CD3 BiSpecific Antibody Also in Development

- Binds cell surface and recombinant GPC-1 and CD3
- Induces early (CD69) and late (CD25) markers of activation in T cells from healthy donors when cultured with GPC-1+ tumour cells
- Mediates killing of GPC-1+ tumour cells by T cells
- Induces the release of pro-inflammatory cytokines (IFN-γ and TNF) from T cells in culture with GPC-1+ tumour cells
- Induces up-regulation of PD-1 in T cells



GlyTherix's Technology Investment Highlights

The technology risks have been reduced significantly based on the pre-clinical and clinical studies completed to date. In addition, GlyTherix has:

- Miltuximab® and Glypican-1 representing a new innovative therapeutic target and antibody
- Miltuximab® will address a clear market need for new therapies to target solid tumours such as prostate, pancreatic, bladder, oesophageal, brain and ovarian cancers.
- A clear development pathway, including market access strategy incorporating regulatory approach, points market differentiation and health economics.
- A clear understanding of the requirements for the development programs for each of the mechanisms of action being investigated.

  The leadership team needed to manage the planned research programs.
- A clear end goal which is to maximize the return on its intellectual property assets

Link to GlyTherix IM

Please download the IM here: https://minomic.box.com/s/km0oxvgkipbbsrfv404giug322oyrdku